盟科药业(688373.SH)：前三季度净亏损1.94亿元

Core Insights - Amgen Pharmaceuticals (688373.SH) reported a total operating revenue of 104 million yuan for the first three quarters of 2025, representing a year-on-year increase of 6.58% [1] - The net profit attributable to shareholders of the parent company was -194 million yuan, which is a reduction in losses by 97.76 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.3 yuan [1]